Skip to main content

Table 7 Suggested therapies requested by the gastroenterologist after their visit

From: Chronic constipation diagnosis and treatment evaluation: the “CHRO.CO.DI.T.E.” study

THERAPIES

878 pts.(%)

IBS-C (%)

FC (%)

NRC (%)

p-value1

Life style recommendations

722 (82.2)

84.7

81.8

74.1

ns

Dietary suggestions

749 (85.3)

85.5

85.8

79.6

ns

Fibre supplements

489 (55.7)

60.7

53.2

55.6

ns

Herbal remedies

46 (5.2)

6.2

4.9

3.7

ns

Probiotics

318 (36.2)

40.4

33.5

42.6

ns

Lactulose/lactitole

58 (6.6)

4.7

7.8

3.7

ns

Macrogol

609 (69.4)

71.6

70.9

42.6 #

<0.0001

Saline laxatives

31 (3.5)

4.0

3.5

1.9

ns

Stimulant laxatives

55 (6.3)

6.2

6.7

1.9

ns

Softening laxatives

46 (5.2)

5.1

5.7

1.9

ns

Prucalopride

126 (14.4)

13.1

15.7

7.4

ns

Suppositories/micro-enemas

198 (22.6)

23.6

21.3

29.6

ns

Enemas

238 (27.1)

29.5

26.6

20.4

ns

Antispasmodics

146 (16.6)

27.6 * **

11.7

11.1

<0.0001

Anti-bloating agents

191 (21.8)

29.1 ^

18.6

16.7

<0.005

Intestinal antibiotics

55 (6.3)

7.3

5.5

9.3

ns

Anxiolytics

108 (12.3)

14.6

11.5

9.3

ns

Antidepressants

60 (6.8)

8.0

6.0

9.3

ns

Psychotherapy

35 (4.0)

6.9 §

2.7

1.9

<0.05

Pelvic floor rehabilitation

169 (19.3)

14.6

22.2 °

13.0

<0.05

Sacral neurostimulation

3 (0.3)

//

0.4

1.9

ns

Anorectal surgery

20 (2.3)

1.5

2.7

1.9

ns

Colectomy

1 (0.1)

//

//

1.9

ns

Other

18 (2.1)

2.2

2.2

//

ns

  1. IBS-C irritable bowel syndrome with constipation, FC functional constipation, NRC patients do not accomplish Rome III criteria
  2. 1 p values are referred to the differences between IBS-C, FC and NRC groups, in particular
  3. # p < 0.0001 vs IBS-C and NRC; * p < 0.0001 vs FC; ** p < 0.05 vs NRC; ^ p < 0.005 vs FC; § p < 0.05 vs FC; ° p < 0.05 vs IBS-C; ns: not statistically significant